Back to search

Article

Discordance between Equivocal HER2 Immunohistochemistry and Fluorescence in Situ Hybridization Analysis among the Breast Carcinoma Patients in Bangladesh: A Series of 75 Cases

2025-11-11

Abstract excerpt

<title>Abstract</title> <p> <bold>Background:</bold> Accurate determination of HER2 status in breast carcinoma is essential for guiding targeted therapy and improving patient outcomes. While immunohistochemistry (IHC) is commonly used as an initial screening method, equivocal (2+) IHC results often require confirmation through fluorescence in situ hybridization (FISH). However, data on the concordance between I...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
50cdd2d5-6739-5b8d-a39c-44383894f1c1
DOI
10.21203/rs.3.rs-8058814/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Discordance between Equivocal HER2 Immunohistochemistry and Fluorescence in Situ Hybridization Analysis among the Breast Carcinoma Patients in Bangladesh: A Series of 75 CasesDOI 10.21203/rs.3.rs-8058814/v1
Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancersSemantic proximity
Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.Semantic proximity
HER2 gene amplification in patients with breast cancer with equivocal IHC resultsSemantic proximity
Comparative Analysis of HER2 Immunohistochemistry (IHC) and Brightfield Dual-Color In Situ Hybridization (DISH) in Lymph Node Metastasized Breast CancerSemantic proximity
Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity
Comparative Analysis of Clinical and Molecular Characteristics in Invasive Ductal Carcinoma of the BreastSemantic proximity
Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort studySemantic proximity
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerSemantic proximity
The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 statusSemantic proximity
Interlaboratory variability of HER2 fluorescence in situ hybridization testing in breast cancer: results of a multicenter proficiency-testing ring study in ChinaSemantic proximity
Invasive Breast Carcinoma with a DCIS-like Growth Pattern: Clinicopathological Features and Diagnostic PitfallsSemantic proximity
Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation PracticeSemantic proximity
Select a neighboring publication to make it the new centre.